Shanghai Fosun Pharmaceutical (SHA:600196) subsidiary Henlius signed a licensing agreement with Dr. Reddy's to develop, produce, and commercialize HLX15 in the US and 42 European countries, including the UK and Switzerland.
HLX15 is a biosimilar of Daratumumab and is intended to treat multiple myeloma, according to a Thursday filing with the Shanghai bourse.
The deal includes an upfront payment of $33 million and potential milestone payments of up to $98.6 million yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.